- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
- Report
- March 2025
- 150 Pages
Global
From €4430EUR$4,850USD£3,788GBP
- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
Thioridazine is an antipsychotic drug used to treat schizophrenia. It is a member of the phenothiazine class of drugs, which are known for their sedative and anti-psychotic effects. Thioridazine works by blocking dopamine receptors in the brain, which helps to reduce the symptoms of schizophrenia. It is usually prescribed in combination with other antipsychotic medications, such as risperidone or olanzapine. Thioridazine is generally well-tolerated, but can cause side effects such as drowsiness, dry mouth, and blurred vision.
The thioridazine market is a small but important part of the overall schizophrenia drug market. It is used to treat a wide range of symptoms, including hallucinations, delusions, and disorganized thinking. It is also used to treat other mental health conditions, such as bipolar disorder and depression.
Some companies in the thioridazine market include Pfizer, Novartis, and Mylan. These companies produce generic versions of the drug, as well as branded versions. Other companies, such as Sun Pharmaceuticals and Dr. Reddy's Laboratories, also produce generic versions of the drug. Show Less Read more